Full Press Release Details
Incannex Healthcare Expands Clinical Advisory
Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch
NEW YORK and MELBOURNE, Australia - June 24, 2025 -
Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company
advancing combination drug therapies for high-impact indications, announces the appointment of Douglas B. Kirsch, M.D., FAAN, FAASM to
its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board.
"We are honored to welcome Dr. Kirsch to the IHL-42X Clinical
Advisory Board," stated Dr. Lou Barbato, Incannex Chief Medical Officer. "His extensive clinical experience and leadership
within the sleep medicine community will be instrumental as we advance IHL-42X through late-stage development. With his addition, our
advisory board continues to strengthen its depth of expertise at a pivotal time for the program."
Dr. Kirsch is a recognized authority in the field of sleep medicine
with a long-standing track record of clinical, academic, and organizational leadership. He currently serves as Medical Director of Atrium
Health Sleep Medicine, where he oversees clinical sleep medicine services across a large, multi-state hospital system while maintaining
an active clinical practice. He is also a Clinical Professor in the Department of Neurology at the Wake Forest School of Medicine and
has previously held faculty appointments at both the University of Michigan Medical School and Harvard Medical School.
Dr. Kirsch served as President of the American Academy of Sleep Medicine
(AASM) from 2018 to 2019 and has played a leading role in national education efforts, including as Program Chair for the SLEEP Meeting
(2012-2014) and Chair of the AASM Sleep Medicine Trends course (2023-2025). His current interests focus on emerging technologies
in sleep medicine and demonstrating the value of sleep care across healthcare systems.
Dr. Kirsch joins recently announced advisors Scott A. Sands, Ph.D.,
Ali Azarbarzin, Ph.D., Nancy Collop, M.D., and Lora J. McGill, M.D., FAAN, in supporting the advancement of IHL-42X, an oral fixed-dose
combination therapy designed to address obstructive sleep apnea by targeting the physiological mechanisms of intermittent hypoxia and
hypercapnia. The Company expects to report topline Phase 2 data from its U.S. RePOSA study in July 2025, with Phase 3 initiation targeted
for later in the year.
IHL-42X is designed to treat obstructive sleep apnea ("OSA")
by targeting its underlying pathophysiology. An oral fixed-dose combination of dronabinol and acetazolamide, IHL-42X is currently advancing
through the RePOSA Phase 2/3 clinical trial, which is expected to enroll more than 560 patients at sites worldwide.
Designed to act synergistically, IHL-42X uniquely targets two physiological
pathways associated with the intermittent hypoxia ("IH") and hypercapnia that characterize OSA. In a prior Australian Phase
2 clinical trial, IHL-42X was shown to reduce the Apnea-Hypopnea Index ("AHI") in all dosage strengths, with the lowest dose
reducing AHI by an average of 51 percent relative to baseline. RePOSA, a global Phase 2/3 clinical trial is underway, evaluating IHL-42X
in individuals with OSA who are either non-compliant, intolerant, or na ve to positive airway pressure devices, including CPAP, with
the Phase 2 portion conducted in the United States. A topline readout from the U.S. Phase 2 portion is anticipated in July 2025.
Unlike weight loss therapies, IHL-42X is uniquely engineered to target
two key physiological pathways, intermittent hypoxia (IH) and hypercapnia, that underlie the pathology of OSA. By targeting these core
mechanisms, IHL-42X offers a differentiated approach that may benefit a wider range of patients, including the 67% of individuals with
OSA who are not classified as obese. OSA affects an estimated 1 billion people globally and approximately 30 million people in the United
States. Despite its high prevalence OSA remains significantly underdiagnosed and undertreated. IHL-42X has the potential to address this
critical gap in care and improve outcomes for millions living with this serious, chronic condition.
About Incannex Healthcare Inc.
is leading the way in developing combination medicines that target the underlying biological pathways associated with chronic conditions,
including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. The company is advancing three clinical-stage
product candidates based on evidence-based innovation and supported by streamlined operations. Incannex's lead clinical program, IHL-42X,
is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in
the treatment of obstructive sleep apnea. In a Phase 2 development program, IHL-675A is an oral fixed-dose combination of cannabidiol
and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. Approved
for Phase 2 clinical development, PSX-001 is an oral synthetic psilocybin treatment for the treatment of generalized anxiety disorder.
Incannex's programs target disorders that have limited, inadequate, or no approved pharmaceutical treatment options. For additional information
on Incannex, please visit our website at www.incannex.com.
Forward Looking Statements
contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things:
Incannex's business strategy, future operations; Incannex's ability to execute on its objectives, prospects, or plans, evaluations and
judgments regarding Incannex's research and development efforts, including any implications that the results of earlier clinical trials
will be representative or consistent with later clinical trials or final results; the expected timing of enrollment for these trials
and the availability of data or results of these trials, and the potential benefits, safety or of Incannex's drug candidates. Forward-looking
statements are statements other than historical facts and relate to future events or circumstances or Incannex's future performance,
and they are based on management's current assumptions, expectations, and beliefs concerning future developments and their potential
effect on Incannex's business; Incannex's ability to obtain the requisite stockholder approval for the exercise of the Series A
Warrants; Incannex's ability to potentially improve its capital structure in the future. These forward-looking statements are subject
to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release
to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements.
These risks and uncertainties include, among others: the continued availability of financing; Incannex's ability to raise capital to
fund continuing operations, to complete capital raising transactions and to potentially improve its capital structure; the impact of
any infringement actions or other litigation brought against Incannex; the success of Incannex's development efforts, including Incannex's
ability to progress its drug candidates through clinical trials on the timelines expected; competition from other providers and products;
that the market for its drug candidates may not grow at the rates anticipated or at all; Incannex's compliance with the various evolving
and complex laws and regulations applicable to its business and its industry; and Incannex's ability to protect its proprietary technology
and intellectual property; and other factors relating to Incannex's industry, its operations and results of operations. The forward-looking
statements made in this press release speak only as of the date of this press release, and Incannex assumes no obligation to update publicly
any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law. Incannex's
reports filed with the U.S. Securities and Exchange Commission (SEC) including its annual report on Form 10-K for the fiscal year ended
June 30, 2024, filed with the SEC on September 30, 2024, and the other reports it files from time to time, including subsequently filed
annual, quarterly and current reports, are made available on Incannex's website upon their filing with the SEC. These reports contain
more information about Incannex, its business and the risks affecting its business, as well as its results of operations for the periods
covered by the financial results included in this press release. For additional information on Incannex, please visit our website at
Investor & Media Contacts